A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer

NCT07454720 | Recruiting Phase 2

• 1 other identifier: SHR-1316-308
• Study Type: interventional
• Target: 165
• Locations: 1 country
• Sites: 2

Brief Summary

The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.

Conditions

Locally Advanced Resectable Rectal Cancer

Outcome Measures

Primary Outcomes (1)

• Phase II: pCR (Pathological Complete Response) rate

  Evaluated by investigators.

  12 months

Secondary Outcomes (8)

• Phase II: Clinical complete response (cCR) rate

  60 months

• Phase II: Disease-free survival (DFS)

  60 months

• Phase II: EFS (Event Free Survival)

  60 months

• Phase II: Tumor regression grade (TRG)

  60 months

• Phase II: R0 resection rate

  60 months

Study Arms (3)

Cohort 1

EXPERIMENTAL

Patients will receive radiotherapy and Adebrelimab in combination with SHR-8068 and chemotherapy as perioperative treatment.

Drug: Adebrelimab in combination with SHR-8068 and chemotherapy

Cohort 2

EXPERIMENTAL

Patients will receive radiotherapy and Adebrelimab combined with chemotherapy as perioperative treatment.

Drug: Adebrelimab combined with chemotherapy

Cohort 3

EXPERIMENTAL

Patients will receive radiotherapy plus chemotherapy as perioperative treatment.

Drug: Chemotherapy

Interventions

Adebrelimab combined with chemotherapy DRUG

Adebrelimab combined with chemotherapy.

Cohort 2

Adebrelimab in combination with SHR-8068 and chemotherapy DRUG

Adebrelimab in combination with SHR-8068 and chemotherapy.

Cohort 1

Chemotherapy DRUG

Chemotherapy.

Cohort 3

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.
• Male or female ≥ 18 years old and ≤75 years old.
• ECOG performance status of 0-1.
• An assessment of resectable locally advanced rectal.
• Has not received any anti-tumor treatment for rectal cancer.
• With a life expectancy of ≥2 years.
• Male participants whose partners are fertile women and fertile female participants must take effective contraceptive measures together with their partners from the time of signing the informed consent form until 6 months after the last administration of the investigational drug or the last radiotherapy. Female participants with fertility must have a negative serum or urine test for human chorionic gonadotropin (HCG) within 7 days before the first administration of the drug (if the serum HCG test is positive, pregnancy should be ruled out and further discussion with the sponsor should be conducted), and they must be not in the lactation period.

You may not qualify if:

• Patients with rectal cancer who have experienced local recurrence after previous treatment.
• Patients with concurrent colon tumors.
• Patients with initially unresectable colorectal cancer as evaluated by researchers or those whose condition is determined by researchers to be intolerant to surgery.
• Clinical or imaging examinations suggest the presence of intestinal obstruction or perforation, or those assessed by researchers as having a relatively high risk of perforation or bleeding.
• With distant metastases.
• Imaging examination of rectal cancer indicated positive lateral lymph nodes.
• Having received surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. for tumors.
• Female participants who are pregnant, breastfeeding or planning to become pregnant during the study period.
• There are uncontrollable mental illnesses and other circumstances known to affect the completion of the research procedures, such as alcohol abuse, drug abuse or drug abuse, and criminal detention.
• Any other factors that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate as judged by investigators.

Sponsors & Collaborators

• Suzhou Suncadia Biopharmaceuticals Co., Ltd.: lead

Study Sites (2)

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

RECRUITING

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China

RECRUITING

MeSH Terms

Interventions

Drug Therapy

Intervention Hierarchy (Ancestors)

Therapeutics

Central Study Contacts

Chuanpei Huang

CONTACT

+86-021-61053363; chuanpei.huang@hengrui.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 25, 2026
• First Posted: March 6, 2026
• Study Start: March 23, 2026
• Primary Completion (Estimated): November 1, 2032
• Study Completion (Estimated): November 1, 2035
• Last Updated: May 5, 2026

Record last verified: 2026-04

Locations

CN (2)